By codifying the removal of regulatory barriers, the limited population pathway provision for certain antimicrobial drugs in the 21st Century Cures Act will incentivize the development of infectious disease drugs that would impact small, specific populations, experts say.
There are several reasons why drugmakers have avoided antimicrobial development – antibiotic development in particular – over the past few...







